A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy

Preterm Birth Clinical Trial

Official title:

A Randomized Clinical Trial of Oral Magnesium Supplementation In Pregnancy for the Prevention of Preterm Birth and Perinatal and Maternal Morbidity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02032186
• Other study ID #: IMIPBMGF
• Secondary ID: 20138
• Status: Completed
• Phase: Phase 3
• Start date: March 2014
• Est. completion date: December 2015

Study information

• Verified date: July 2020
• Source: Professor Fernando Figueira Integral Medicine Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators propose a preventive strategy that may reduce the risk of placental vascular disease and its negative consequences for both the fetus (e.g., poor fetal growth or stillbirth)and mother (e.g., the hypertensive disorders of pregnancy), and which, in turn, should reduce the need for indicated preterm delivery. This strategy is a multicenter, randomized double-blind, placebo-controlled clinical trial (RCT) comparing magnesium citrate supplementation with placebo, each starting at 12 to 20 weeks gestation and continued until delivery. Magnesium citrate is a safe and inexpensive compound that is easily absorbed by the intestinal tract. The results of this RCT may be especially relevant in low and middle income countries that have high rates of prematurity, and limited resources for acute newborn and maternal care.

Description:

The investigators will complete a multicenter double-blind, placebo-controlled randomized clinical trial of oral Mg++citrate supplementation.

Setting: (1) Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife-Pernambuco: IMIP maintains the largest hospital in Brazil exclusively dedicated to Brazilian Health System, [Sistema Único de Saúde] (SUS). IMIP has 1,032 beds and performs more than 2,000 clinical daily visits. IMIP enrolls about 6,000 deliveries per year and has an obstetric intensive care unit. IMIP is a teaching hospital (degree programs in medicine, nursing, nutrition, physical therapy, pharmacology and psychology and postgraduate - residency, master and doctoral) and is a reference center to woman assistance in Northeast Brazil by the Ministry of Health of the Federal Government. (2) Dom Malan Hospital (HDM), Petrolina-Pernambuco: HDM assists the population of about 1 million people in 55 municipalities of Pernambuco, Bahia and Piauí States. HDM assists about 1,500 pregnant women monthly in emergency service and performs an average of 528 prenatal visits including high-risk pregnancy (±35%). HDM enrolls about 600 deliveries/month and also has an obstetric intensive care unit. HDM has a teaching program for medical and nursing students and also develops a residence program.

Data collection will be conducted from March 2014 to August 2015. Study population will be all pregnant women since they started their prenatal care visits at IMIP and/or HDM before 20th gestational week.

At a sample size of 1000 women assigned to placebo and 2000 women assigned to Mg++ citrate, with power of 80% and a 2-sided P-value of 0.05, we will be able to detect at least a 22% relative risk reduction in the primary perinatal composite outcome, assuming a primary perinatal composite outcome rate of 18% in the placebo group and 14% in the Mg++ group. In Recife there are 25,000 births a year. Of these 25,000, at least 30% (7,500) would attend one of the study prenatal clinics, & of those 7,500, 60% (4,500) would meet ≥1 of the eligibility criteria. With a participation rate of 50%, 2,250 women can be recruited in a year, thus requiring 1.25 years to recruit all women, and 2 years ascertain all primary outcome events.

A systematic sample will be obtained from low risk pregnant women who begin prenatal care visits before 20th gestational week at IMIP or HDM, during the study period.

Pregnant women admitted to the study will continue with their normal attendance at IMIP or HDM. There will be no interference by the researchers in obstetric management of patients involved in the study. All pregnant women will be followed until the postpartum and the newborn until hospital discharge.Hematologic and urine tests will be performed every month (four times) to evaluate Mg++ concentration from each pregnant woman. After inclusion in the study, pregnant women will be monitored monthly until delivery. Pregnant women who do not attend the clinic visit schedule, will be contacted by phone and/or visited. Losses after randomization will be registered with the respective reason.

Randomization will be performed by the "Random Allocation" software, version 1.0. After signing the consent form each participant will be allocated to the "magnesium" or "placebo" group.

Oral Mg++citrate, 150 mg twice daily. Each capsule will contained 150 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.

Compliance/adherence, adverse events, and clinical intercurrence will be monitored by the research team at each routine prenatal visit until the completion of the treatment. Adherence will be defined as the ingestion of at least 80% of the prescribed dose.

Quality Control of Information: The forms will be completed by the researcher and stored in a specific folder. All data collection will be checked by a monitor.

Analysis: Primary and secondary endpoints will be compared between groups. Continuous data will be tested using the unpaired two-tailed t-test (if normally distributed) and the Mann-Whitney U-test (if non-normally distributed). Fisher's exact test will be used for nominal data. A significance value <0.05 will be used in all tests.

Ethical aspects: This project will be submitted to IMIP's and Dom Malan Hospital Committee on Ethical Research. Each participating woman in the study will sign an informed consent. They will be free to withdraw from the trial at any time. The trial will be conducted according to the WHO guidelines for good clinical trial practice.

To ensure the safety of participants and the validity and integrity of the data a Data and Safety Monitoring Board (DSMB) will be created to follow the study. The DSMB will consist of 5 experts members representing the following institutions and not involved with this trial: Bill and Melinda Gates Foundation, Ministry of Health of Brazilian Government, IMIP, Dom Malan Hospital and an statistician. The DSMB will periodically review the accumulated study data for pregnant women and fetus safety, study conduct, progress and efficacy. DSMB also can make recommendations to continuation, modification or termination of this trial.

Conflict of interest: Nothing to declare. This project will be entered in the international registry of clinical trials.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3000
• Est. completion date: December 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• gestational age before 20th

• low risk pregnancy

Exclusion Criteria:

• high magnesium serum

Related Conditions & MeSH terms

• Extreme Immaturity
• Magnesium Deficiency
• Premature Birth
• Preterm Birth

Intervention

Drug:
• Magnesium citrate
Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.

Locations

Country	Name	City	State
Brazil	Instituto de Medicina Integral Prof Fernando Figueira (IMIP)	Recife	Pernambuco

Sponsors (1)

Lead Sponsor	Collaborator
Professor Fernando Figueira Integral Medicine Institute

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Preterm birth	Delivery before 37 gestational week	Delivery
Secondary	Gestational diabetes mellitus		24th 28th gestational week
Secondary	Pre-eclampsia		24th to 38th gestational week
Secondary	Low birth weight		Delivery